AICT (ADVANCED INSTITUTES OF CONVERGENCE TECHNOLOGY);THERAGEN ETEX CO., LTD
发明人:
Seong Jin KIM,Jin Ah PARK,Eun Jin BAE
申请号：
US16413014
公开号：
US20190360054A1
申请日:
2019.05.15
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present disclosure relates to a method of diagnosing metastatic cancer or taxane-based drug-resistant cancer, including: measuring an LMCD1 expression level from a complex formed by bringing, into contact with a sample isolated from a subject, an antibody, peptide, protein, or combination thereof that specifically binds to an LMCD1 protein or a fragment thereof； or a probe, primer, nucleotide, or combination thereof that specifically binds to a nucleotide sequence encoding the LMCD1 protein； and comparing the measured LMCD1 expression level of the sample with a measured LMCD1 expression level of a control, and a kit for diagnosing metastatic cancer or taxane-based drug-resistant cancer, including a composition for diagnosing metastatic cancer or taxane-based drug-resistant cancer.
